The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
The anti‐epileptic drug levetiracetam reverses the inhibition by negative allosteric modulators of neuronal GABA‐ and glycine‐gated currents
Open accessAbstract
In this study in vitro and in vivo approaches were combined in order to investigate if the anti‐epileptic mechanism(s) of action of levetiracetam (LEV; Keppra®) may involve modulation of inhibitory neurotransmission. GABA‐ and glycine‐gated currents were studied in vitro using whole‐cell patch‐clamp techniques applied on cultured cerebellar granule, hippocampal and spinal neurons. Protection against clonic convulsions was assessed in vivo in sound‐susceptible mice. The effect of LEV was compared with reference anti‐epileptic drugs (AEDs): carbamazepine, phenytoin, valproate, clonazepam, phenobarbital and ethosuximide. LEV contrasted the reference AEDs by an absence of any direct effect on glycine‐gated currents. At high concentrations, beyond therapeutic relevance, it induced a small reduction in the peak amplitude and a prolongation of the decay phase of GABA‐gated currents. A similar action on GABA‐elicited currents was observed with the reference AEDs, except ethosuximide. These minor direct effects contrasted with a potent ability of LEV (EC 50=1 – 10 μ M) to reverse the inhibitory effects of the negative allosteric modulators zinc and β‐carbolines on both GABA A and glycine receptor‐mediated responses. Clonazepam, phenobarbital and valproate showed a similar ability to reverse the inhibition of β‐carbolines on GABA‐gated currents. Blockade of zinc inhibition of GABA responses was observed with clonazepam and ethosuximide. Phenytoin was the only AED together with LEV that inhibited the antagonism of zinc on glycine‐gated currents and only clonazepam and phenobarbital inhibited the action of DMCM. LEV (17 mg kg−1) produced a potent suppression of sound‐induced clonic convulsions in mice. This protective effect was significantly abolished by co‐administration of the β‐carboline FG 7142, from a dose of 5 mg kg−1. In contrast, the benzodiazepine receptor antagonist flumazenil (up to 10 mg kg−1) was without any effect on the protection afforded by LEV. The results of the present study suggest that a novel ability to oppose the action of negative modulators on the two main inhibitory ionotropic receptors may be of relevance for the anti‐epileptic mechanism(s) of action of LEV. British Journal of Pharmacology(2002)136, 659–672; doi:10.1038/sj.bjp.0704766
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hamill, O. P., Marty, A., Neher, E., Sakmann, B., & Sigworth, F. J. (1981) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/bf00656997 · Cited by 18,436
Down-Regulation of Na+/K+ATPase Activity by Human Parvovirus B19 Capsid Protein VP1
Almilaji, A., Szteyn, K., Fein, E., Pakladok, T., Munoz, C., Elvira, B., Towhid, S. T., Alesutan, I., Shumilina, E., Bock, C.-T., et al. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350083 · Cited by 8,675
Regulation of the Voltage Gated K+ Channel Kv1.3 by Recombinant Human Klotho Protein
Almilaji, A., Honisch, S., Liu, G., Elvira, B., Ajay, S. S., Hosseinzadeh, Z., Ahmed, M., Munoz, C., Sopjani, M., & Lang, F. (2014) · Kidney and Blood Pressure Research · doi:10.1159/000368472 · Cited by 5,592
Growth of a rat neuroblastoma cell line in serum-free supplemented medium.
Bottenstein, J. E., & Sato, G. H. (1979) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.76.1.514 · Cited by 2,276
Turski, W. A., Cavalheiro, E. A., Schwarz, M., Czuczwar, S. J., Kleinrok, Z., & Turski, L. (1983) · Behavioural Brain Research · doi:10.1016/0166-4328(83)90136-5 · Cited by 1,113
Mehta, A. K., & Ticku, M. K. (1999) · Brain Research Reviews · doi:10.1016/s0165-0173(98)00052-6 · Cited by 625
Antiepileptic Drug Mechanisms of Action
Macdonald, R. L., & Kelly, K. M. (1995) · Epilepsia · doi:10.1111/j.1528-1157.1995.tb05996.x · Cited by 591
Kainic acid as a tool for the study of temporal lobe epilepsy
Victor Nadler, J. (1981) · Life Sciences · doi:10.1016/0024-3205(81)90659-7 · Cited by 576
Braestrup, C., Nielsen, M., & Olsen, C. E. (1980) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.77.4.2288 · Cited by 541
Pharmacokinetic profile of levetiracetam
Patsalos, P. N. (2000) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(99)00052-2 · Cited by 519
Cited by
The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam
Lynch, B. A., Lambeng, N., Nocka, K., Kensel-Hammes, P., Bajjalieh, S. M., Matagne, A., & Fuks, B. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0308208101 · Cited by 1,610
Self-citationMechanisms of action of currently used antiseizure drugs
Sills, G. J., & Rogawski, M. A. (2020) · Neuropharmacology · doi:10.1016/j.neuropharm.2020.107966 · Cited by 489
Drug Resistance in Epilepsy: Putative Neurobiologic and Clinical Mechanisms
Schmidt, D., & Löscher, W. (2005) · Epilepsia · doi:10.1111/j.1528-1167.2005.54904.x · Cited by 482
Paulus, W., Classen, J., Cohen, L. G., Large, C. H., Di Lazzaro, V., Nitsche, M., Pascual-Leone, A., Rosenow, F., Rothwell, J. C., & Ziemann, U. (2008) · Brain Stimulation · doi:10.1016/j.brs.2008.06.002 · Cited by 414
Double-blind placebo-controlled trial of adjunctive levetiracetam in pediatric partial seizures
Glauser, T. A., Ayala, R., Elterman, R. D., Mitchell, W. G., Van Orman, C. B., Gauer, L. J., & Lu, Z. (2006) · Neurology · doi:10.1212/01.wnl.0000217916.00225.3a · Cited by 258
Gillard, M., Chatelain, P., & Fuks, B. (2006) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2006.02.022 · Cited by 148
Levetiracetam Mechanisms of Action: From Molecules to Systems
Contreras-García, I. J., Cárdenas-Rodríguez, N., Romo-Mancillas, A., Bandala, C., Zamudio, S. R., Gómez-Manzo, S., Hernández-Ochoa, B., Mendoza-Torreblanca, J. G., & Pichardo-Macías, L. A. (2022) · Pharmaceuticals · doi:10.3390/ph15040475 · Cited by 131
“Another action of LEV in the GABAergic system involves the ability to reverse the inhibitory effects of the negative allosteric modulators β-carbolines and zinc on both GABAA and glycine receptors, the two main ionotropic inhibitory receptor systems in the brain [145].”
BackgroundMethodInfluentialPollack, M. H., Jensen, J. E., Simon, N. M., Kaufman, R. E., & Renshaw, P. F. (2008) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2007.11.023 · Cited by 112
Wu, P.-P., Cao, B.-R., Tian, F.-Y., & Gao, Z.-B. (2024) · Neuroscience Bulletin · doi:10.1007/s12264-023-01138-2 · Cited by 35
Metadata
- Authors
- Rigo, J., Hans, G., Nguyen, L., Rocher, V, Belachew, S., Malgrange, B., Leprince, P., Moonen, G., Selak, I., Matagne, A., & Klitgaard, H.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2002-07
- Volume
- 136
- Issue
- 5
- Pages
- 659-672
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W2087243332
- Cited by
- 336
- References
- 52
- FWCI
- 13.94
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.